Sugi Predict

Sugi Predict / Compounds / SCHEMBL6906096

SCHEMBL6906096

SCHEMBL6906096

C#Cc1cn([C@H]2C[C@H](OC(C)=O)[C@@H](COC(C)=O)O2)c(=O)nc1N

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DNMT1 P26358 5/20 0.35
▸ ADRB1 P08588 1/20 0.35
▸ RNASE1 P07998 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ DNMT3B Q9UBC3 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2578960 0.87 POLB (0.35) RNASE1CA12CA1CA2CA9
SCHEMBL8894799 0.85 ALB (0.47) DNMT1ADRB1RNASE1CA12CA1
SCHEMBL2582676 0.83 TLR7 (0.33) CA12CA1CA2CA9LMNA
SCHEMBL9803710 0.83 DNMT1 (0.40) DNMT1ADRB1RNASE1CA12CA1
SCHEMBL13413018 0.82 RNASE1 (0.46) RNASE1
SCHEMBL4174764 0.82 RNASE1 (0.46) RNASE1
SCHEMBL2584829 0.81 LMNA (0.48) CA12CA1CA2CA9LMNA
SCHEMBL2580798 0.80 POLB (0.35) DNMT1ADRB1RNASE1CA12CA1
SCHEMBL10063813 0.80 DNMT1 (0.56) DNMT1ADRB1CA12CA1CA2
SCHEMBL118662 0.80 DNMT1 (0.56) DNMT1ADRB1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699690-B2 LINKED AND CONTROLLING THE EXPRESSION OF A HETEROLOGOUS ENZYME, FOR EXAMPLE VARICELLA ZOSTER VIRUS THYMIDINE KINASE OR NON-MAMMALIAM CYTOSINE DEAMINASE SMITHKLINE BEECHAM CORPORATION 2004-03-02 — — US disclosed
US-20020055482-A1 Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase SMITHKLINE BEECHAM CORPORATION 2002-05-09 — — US disclosed
US-6337209-B1 A CHIMERIC MOLECULE; THERAPY FOR COLORECTAL CANCER GLAXO WELLCOME INC. 2002-01-08 — — US disclosed
US-6300490-B1 EXPRESSION VECTOR CODING CYTOSINE DEAMINASE; FOR USE IN THE TREATMENT OF CANCERS GLAXO WELLCOME INC. 2001-10-09 — — US disclosed
EP-0486477-A2 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound THE WELLCOME FOUNDATION LIMITED (GB) 1992-05-20 — — EP disclosed
US-5028596-A Varicella Zoster BURROUGHS WELLCOME CO. (US) 1991-07-02 — — US disclosed
EP-0417560-A1 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-03-20 — — EP disclosed
EP-0272065-A2 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1988-06-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055482-A1 Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase TK1, CDA, DCTD DNMT1 64/4885ADRB1 4578/4885RNASE1 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.